Immunosuppression in Rheumatologic and Auto-immune Disease

Jayatilleke, Arundathi

doi:10.1007/164_2021_551

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When combined with antibiotics, it has the ability to effectively inhibit inflammation. Furthermore, immunosuppressive agents are effective in the treatment of cancer (Rollan et al., 2022 ) and some diseases caused by abnormal autoimmunity (Jayatilleke, 2022 ). Comparatively to other therapies, immunosuppressive therapies target immune cells, specifically regulating their immune response.…”

Section: Introductionmentioning

confidence: 99%

Research progress of ophthalmic preparations of immunosuppressants

Liu

Yan³

et al. 2023

Drug Delivery

View full text Add to dashboard Cite

Immune ophthalmopathy is a collection of autoimmune eye diseases. Immunosuppressants are drugs that can inhibit the body’s immune response. Considering drug side effects such as hepatorenal toxicity and the unique structure of the eye, incorporating immunosuppressants into ophthalmic nanodrug delivery systems, such as microparticles, nanoparticles, liposomes, micelles, implants, and in situ gels, has the advantages of improving solubility, increasing bioavailability, high eye-target specificity, and reducing side effects. This study reviews recent research and applications of this aspect to provide a reference for the development of an ophthalmic drug delivery system.

show abstract

Section: Introductionmentioning

confidence: 99%